New drug cocktail offers hope for head and neck cancer patients who failed immunotherapy

NCT ID NCT06725368

First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 16 times

Summary

This study is for adults with advanced head and neck cancer that has returned or spread and no longer responds to standard first-line immunotherapy (pembrolizumab) with or without chemotherapy. Researchers want to see if a combination of three drugs—carboplatin, paclitaxel, and cetuximab—can shrink tumors or slow the disease. The trial will enroll 46 participants in France and follow them for 12 months, tracking tumor response, side effects, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Besançon

    RECRUITING

    Besançon, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre Hospitalier de Colmar

    RECRUITING

    Colmar, 68024, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Paul Strauss

    RECRUITING

    Strasbourg, 67033, France

    Contact Email: •••••@•••••

    Contact

    Contact

    Contact

  • Centre hospitalier Régional de Metz-Thionville

    RECRUITING

    Ars-Laquenexy, 57085, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Institut de cancérologie de Lorraine

    RECRUITING

    Vandœuvre-lès-Nancy, 54519, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.